A Near Point of Care Test for Interleukin 1B During Human Ex-Vivo Lung Perfusion
The ability to confidently identify which extended criteria donor lungs can be successfully reconditioned via ex-vivo lung perfusion (EVLP) and will function well post transplant is essential. IL-1 β is a promising early perfusate marker shown to differentiate between 1-year post-Tx survival and mortality with high precision in EVLP recipients (p=0.005, AUC=0.93). However, the typical EVLP assessment time before a decision on transplant suitability has to be made is as short as two-four hours . For any biomarker technology to have real clinical relevance it has to be highly accurate and able to deliver a result available to the clinical team at time of decision-making.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: A.S. Andreasson, W. Laroy, J.H. Dark, A.J. Fisher Source Type: research
More News: Cardiology | Heart | Heart Transplant | Lung Transplant | Perfusion | Transplant Surgery | Transplants